Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.
about
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney diseaseGlucose lowering therapies for chronic kidney disease and kidney transplantationAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseasePharmacologic management of chronic reno-cardiac syndromeSystematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal ImpairmentNeurological complications in chronic kidney disease patients.Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trialsEffects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.Low glomerular filtration rate, recurrent stroke risk, and effect of renin-angiotensin system modulation.Low glomerular filtration rate and risk of stroke: meta-analysis.Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial.Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials.Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.Kidney function and estimated vascular risk in patients with primary dyslipidemiaImpact of renal transplantation on cardiac morphological and functional characteristics in children and adults.Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference.Reno-cerebrovascular disease: linking the nephron and neuron.Combination perindopril/indapamide for the treatment of hypertension: a review.PROGRESS: Prevention of Recurrent Stroke.Pharmacologic treatment of hypertension in patients with chronic kidney disease.Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.Arterial stiffness and increased cardiovascular risk in chronic kidney disease.Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.Challenges of conducting a trial of uric-acid-lowering therapy in CKD.Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama Study.Medication-prescribing patterns of primary care physicians in chronic kidney disease.Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.
P2860
Q24188192-AD06B3A5-4ACC-4A54-992F-568173B1BC20Q24201814-53333652-BE89-41C0-A0C5-D09EAFC0371BQ24235834-15256521-F069-4292-8B78-F336360274A9Q26829812-231B00B6-8E13-46DF-8E33-7142622481DCQ28075368-641BEB07-2E88-4974-BC4D-553DE5A055BEQ30252095-10261891-A025-4874-AF73-723889000213Q33413288-50041D1E-97FF-4B08-8A4B-A194759694ADQ33859007-7D5A878E-B635-4AE0-B8DC-6B9FD80581C3Q34053329-A2DD3A03-438D-416E-96CA-4BC86757842DQ34168779-BE2609E9-FFAE-4CE2-A124-B625155F27F9Q34632829-CBFF0F35-C938-4D3B-A910-2913DC0C7BF3Q35995026-ACF58B4E-C6BA-40C5-A477-E2123A695D87Q36443751-F61E3D82-485A-49E6-895F-E48F7E53DB49Q37213061-0CE22167-97CE-46EE-A655-86C1E64EB2FFQ37245464-6ED0804D-D51A-4988-842E-AE079913E266Q37399686-9516CDCA-E889-4408-BF0B-BEE332ECD77EQ37684944-AC5D5EA5-FE5E-4829-BB14-919D74CE04B9Q37759964-AEC27017-3440-4F68-912A-AB8E56BCB336Q37838428-C6C4543E-E952-4F5D-82EF-2C6644E3C412Q37886189-95CF288C-0084-41F2-8F52-359A5C56C025Q37928134-6CC7A097-171B-4A4E-B195-59BAECBE5967Q38095805-61041316-A661-46A7-8F4C-37B673348A42Q38138322-B059BBA7-4F9A-4C88-BC7D-F64EB0492B7FQ38492683-B05F4B2F-B5C5-49C9-9351-117566EED9F1Q38545232-61874D1E-890A-4D96-A119-D71770CB5510Q44235739-61F11AE6-8F67-4644-AD13-FD9E1737BF72Q44475110-A562D79C-CC1D-4A3C-BA8C-C23B40072421Q44707707-B20B9F34-E5B7-4F63-B6DC-4B2A393B549FQ53494879-99486C76-3C87-40CA-9126-9C93AD935510
P2860
Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Chronic kidney disease, cardio ...... data from the PROGRESS study.
@ast
Chronic kidney disease, cardio ...... data from the PROGRESS study.
@en
type
label
Chronic kidney disease, cardio ...... data from the PROGRESS study.
@ast
Chronic kidney disease, cardio ...... data from the PROGRESS study.
@en
prefLabel
Chronic kidney disease, cardio ...... data from the PROGRESS study.
@ast
Chronic kidney disease, cardio ...... data from the PROGRESS study.
@en
P2093
P50
P356
P1476
Chronic kidney disease, cardio ...... data from the PROGRESS study.
@en
P2093
Bruce Neal
Hisatomi Arima
Martin Gallagher
Stephen Macmahon
Toshiharu Ninomiya
P304
P356
10.1681/ASN.2007020256
P577
2007-09-05T00:00:00Z